Serum hepcidin levels, iron dyshomeostasis and cognitive loss in Alzheimer'S Disease

Aging and Disease

Volumn 8, Issue 2, 2017, Pages 215-227

  Sternberg, Zohara ^a   Hu, Zihua ^b   Sternberg, Daniel ^a   Waseh, Shayan ^c   Quinn, Joseph F ^d   Wild, Katharine ^d   Kaye, Jeffrey ^d   Zhao, Lin ^c   Garrick, Michael ^c  

^a Buffalo General Medical Center   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Ferritin; Inflammation; Iron homeostasis; Mild cognitive impairment; Percent transferrin saturation; Serum biomarker

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FERRITIN; HEPCIDIN; IRON; TRANSFERRIN;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM DISORDER; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROIMAGING;

EID: 85018490734     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2016.0811     Document Type: Article

References (62)

1. Anonymous (2014). Alzheimer's Disease Facts and Figures. Alz.org
2. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. (2009). Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol, 65: 650-657
3. Wolf AB, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, et al. (2013). Apolipoprotein E as a beta-amyloid-independent factor in Alzheimer's disease. Alzheimers Res Ther, 5: 38
4. Petersen RC (2011). Clinical practice. Mild cognitive impairment. N Engl J Med, 364: 2227-2234
5. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008). Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement, 4: 38-48
6. Irizarry MC (2004). Biomarkers of Alzheimer disease in plasma. NeuroRx, 1: 226-234
7. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. (2003). Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology, 61: 1185-1190
8. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD (2005). Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry, 13: 914-917
9. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. (2007). Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol, 64: 354-362
10. Jomova K, Vondrakova D, Lawson M, Valko M (2010). Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem, 345: 91-104
11. Urrutia PJ, Mena NP, Nunez MT (2014). The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front Pharmacol, 5: 38
12. Greenough MA, Camakaris J, Bush AI (2013). Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int, 62: 540-555
13. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Jr., Cohen ML, et al. (2010). Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis, 19: 363-372
14. Gallagher JJ, Finnegan ME, Grehan B, Dobson J, Collingwood JF, Lynch MA (2012). Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J Alzheimers Dis, 28: 147-161
15. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, et al. (2002). An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem, 277: 45518-45528
16. Rogers JT, Bush AI, Cho HH, Smith DH, Thomson AM, Friedlich AL, et al. (2008). Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans, 36: 1282-1287
17. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, et al. (2010). Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem, 285: 31217-31232
18. McCarthy RC, Park YH, Kosman DJ (2014). sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep, 15: 809-815
19. Garrick M (2011). Human iron transporters. Genes & Nutrition, 6: 45-54
20. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984). Transferrin receptor on endothelium of brain capillaries. Nature, 312: 162-163
21. Ganz T (2003). Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 102: 783-788
22. Rossi E (2005). Hepcidin-the iron regulatory hormone. Clin Biochem Rev, 26: 47-49
23. Wang Q, Du F, Qian Z-M, Ge XH, Zhu L, Yung WH, et al. (2008). Lipopolysaccharide Induces a Significant Increase in Expression of Iron Regulatory Hormone Hepcidin in the Cortex and Substantia Nigra in Rat Brain. Endocrinology, 149: 3920-3925
24. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. (2000). Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature, 403: 776-781
25. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306: 2090-2093
26. Weiss G, Goodnough LT (2005). Anemia of chronic disease. N Engl J Med, 352: 1011-1023
27. Kell DB, Pretorius E (2014). Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics, 6: 748-773
28. Herbert V, Jayatilleke E, Shaw S, Rosman AS, Giardina P (1997). Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells, 15: 291-296
29. ten Kate J, Wolthuis A, Westerhuis B, van Deursen C (1997). The iron content of serum ferritin: physiological importance and diagnostic value. Eur J Clin Chem Clin Biochem, 35: 53-56
30. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, et al. (2010). Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood, 116: 1574-1584
31. Wang W, Grier DD, Woo J, Ward M, Sui G, Torti SV, et al. (2013). Ferritin H is a novel marker of early erythroid precursors and macrophages. Histopathology, 62: 931-940
32. Leimberg MJ, Prus E, Konijn AM, Fibach E (2008). Macrophages function as a ferritin iron source for cultured human erythroid precursors. J Cell Biochem, 103: 1211-1218
33. Bowman GL, Quinn JF (2008). Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future. Aging health, 4: 47-55
34. Heppner FL, Ransohoff RM, Becher B (2015). Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci, 16: 358-372
35. Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003). Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry, 74: 1200-1205
36. Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014). Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol, 50: 534-544
37. Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM (1995). Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem, 270: 15285-15293
38. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, et al. (2004). Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell, 119: 529-542
39. Harrison PM, Arosio P (1996). The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta, 1275: 161-203
40. Koorts AM, Viljoen M (2007). Ferritin and ferritin isoforms II: protection against uncontrolled cellular proliferation, oxidative damage and inflammatory processes. Arch Physiol Biochem, 113: 55-64
41. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, Torti FM (2000). Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol, 20: 5818-5827
42. Arosio P, Yokota M, Drysdale JW (1976). Structural and immunological relationships of isoferritins in normal and malignant cells. Cancer Res, 36: 1735-1739
43. Worwood M, Brook JD, Cragg SJ, Hellkuhl B, Jones BM, Perera P, et al. (1985). Assignment of human ferritin genes to chromosomes 11 and 19q13.3-19qter. Hum Genet, 69: 371-374
44. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995). A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem, 65: 717-724
45. Saresella M, Marventano I, Calabrese E, Piancone F, Rainone V, Gatti A, et al. (2014). A complex proinflammatory role for peripheral monocytes in Alzheimer's disease. J Alzheimers Dis, 38: 403-413
46. Raghavan N (2015). How do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond. Arch Clin Neuropsycho, 30: 478
47. House MJ, St Pierre TG, Milward EA, Bruce DG, Olynyk JK (2010). Relationship between brain R(2) and liver and serum iron concentrations in elderly men. Magn Reson Med, 63: 275-281
48. Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. (2008). Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain, 131: 2443-2454
49. Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, et al. (2010). Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. J Alzheimers Dis, 20: 647-657
50. Jack CR, Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 132: 1355-1365
51. Nunes A, Marques SM, Quintanova C, Silva DF, Cardoso SM, Chaves S, et al. (2013). Multifunctional iron-chelators with protective roles against neurodegenerative diseases. Dalton Trans, 42: 6058-6073
52. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, et al. (2011). Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol, 122: 401-413
53. Meadowcroft MD, Peters DG, Dewal RP, Connor JR, Yang QX (2015). The effect of iron in MRI andtransverse relaxation of amyloid-beta plaques in Alzheimer's disease. NMR Biomed, 28: 297-305
54. Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, et al. (2007). The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett, 427: 127-131
55. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB (2004). Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA, 291: 711-717
56. Swaminathan S, Fonseca VA, Alam MG, Shah SV (2007). The role of iron in diabetes and its complications. Diabetes Care, 30: 1926-1933
57. Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ (2010). Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism, 59: 380-384
58. Kulaksiz H, Fein E, Redecker P, Stremmel W, Adler G, Cetin Y (2008). Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol, 197: 241-249
59. Aigner E, Felder TK, Oberkofler H, Hahne P, Auer S, Soyal S, et al. (2013). Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem, 24: 112-117
60. Adolfsson R, Bucht G, Lithner F, Winblad B (1980). Hypoglycemia in Alzheimer's disease. Acta Med Scand, 208: 387-388
61. Muratli S, Tufan F, Soyluk O, Bahat G, Karan MA (2015). Importance of hypoglycemia on the risk of Alzheimer's disease in elderly subjects with diabetes mellitus. Clin Interv Aging, 10: 1789-1791
62. Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, et al. (2015). Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. ACS Chem Neurosci, 6: 398-402